179 related articles for article (PubMed ID: 37533407)
1. Pharmacological NF-κB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities.
Gil da Costa RM; Levesque C; Bianchi-Frias D; Chatterjee P; Lam HM; Santos C; Coleman IM; Ferreirinha P; Vilanova M; Pinto da Cunha N; Carvalho H; Moreira-Pais A; Faustino-Rocha A; Neto T; Batista da Costa J; Wright JL; Ferreira R; Oliveira PA; Mendes J; Bastos MMSM; Colaço B; Lopes C; Black PC; Sweeney CJ; Nelson PS
Mol Oncol; 2023 Dec; 17(12):2709-2727. PubMed ID: 37533407
[TBL] [Abstract][Full Text] [Related]
2. Interruption of the long non-coding RNA HOTAIR signaling axis ameliorates chemotherapy-induced cachexia in bladder cancer.
Hu CY; Su BH; Lee YC; Wang CT; Yang ML; Shen WT; Fu JT; Chen SY; Huang WY; Ou CH; Tsai YS; Kuo FC; Shiau AL; Shieh GS; Wu CL
J Biomed Sci; 2022 Dec; 29(1):104. PubMed ID: 36471329
[TBL] [Abstract][Full Text] [Related]
3. URGCP/URG4 promotes apoptotic resistance in bladder cancer cells by activating NF-κB signaling.
Wu M; Chen J; Wang Y; Hu J; Liu C; Feng C; Zeng X
Oncotarget; 2015 Oct; 6(31):30887-901. PubMed ID: 26429874
[TBL] [Abstract][Full Text] [Related]
4. ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals.
Huang CP; Chen J; Chen CC; Liu G; Zhang Y; Messing E; Yeh S; Chang C
J Exp Clin Cancer Res; 2019 Jun; 38(1):275. PubMed ID: 31234917
[TBL] [Abstract][Full Text] [Related]
5. Dimethylaminoparthenolide reduces the incidence of dysplasia and ameliorates a wasting syndrome in HPV16-transgenic mice.
Santos JMO; Moreira-Pais A; Neto T; Peixoto da Silva S; Oliveira PA; Ferreira R; Mendes J; Bastos MMSM; Lopes C; Casaca F; Silva S; Sweeney C; Medeiros R; Gil da Costa RM
Drug Dev Res; 2019 Sep; 80(6):824-830. PubMed ID: 31301186
[TBL] [Abstract][Full Text] [Related]
6. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
7. NF-κB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT.
Nakshatri H; Appaiah HN; Anjanappa M; Gilley D; Tanaka H; Badve S; Crooks PA; Mathews W; Sweeney C; Bhat-Nakshatri P
Cell Death Dis; 2015 Jan; 6(1):e1608. PubMed ID: 25611383
[TBL] [Abstract][Full Text] [Related]
8. DMAPT inhibits NF-κB activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo.
Mendonca MS; Turchan WT; Alpuche ME; Watson CN; Estabrook NC; Chin-Sinex H; Shapiro JB; Imasuen-Williams IE; Rangel G; Gilley DP; Huda N; Crooks PA; Shapiro RH
Free Radic Biol Med; 2017 Nov; 112():318-326. PubMed ID: 28782644
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.
Kashiwagi E; Ide H; Inoue S; Kawahara T; Zheng Y; Reis LO; Baras AS; Miyamoto H
Oncotarget; 2016 Aug; 7(31):49169-49179. PubMed ID: 27322140
[TBL] [Abstract][Full Text] [Related]
10. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer.
Ito Y; Kikuchi E; Tanaka N; Kosaka T; Suzuki E; Mizuno R; Shinojima T; Miyajima A; Umezawa K; Oya M
BMC Cancer; 2015 Apr; 15():324. PubMed ID: 25926105
[TBL] [Abstract][Full Text] [Related]
12. MiR-192/NKRF axis confers lung cancer cell chemoresistance to cisplatin via the NF-κB pathway.
Li Y; Zu L; Wu H; Zhang F; Fan Y; Pan H; Du X; Guo F; Zhou Q
Thorac Cancer; 2022 Feb; 13(3):430-441. PubMed ID: 34953057
[TBL] [Abstract][Full Text] [Related]
13. Fluoxetine inactivates STAT3/NF-κB signaling and promotes sensitivity to cisplatin in bladder cancer.
Yang CJ; Tan ZL; Yang JD; Hsu FT; Chiang CH
Biomed Pharmacother; 2023 Aug; 164():114962. PubMed ID: 37276643
[TBL] [Abstract][Full Text] [Related]
14. CD19
Jiang Q; Fu Q; Chang Y; Liu Z; Zhang J; Xu L; Zhu Y; Wang Y; Zhang W; Xu J
Cancer Immunol Immunother; 2019 Jan; 68(1):45-56. PubMed ID: 30259082
[TBL] [Abstract][Full Text] [Related]
15. NF-κB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression.
Sun Y; Guan Z; Liang L; Cheng Y; Zhou J; Li J; Xu Y
Int J Oncol; 2016 Jan; 48(1):225-34. PubMed ID: 26647959
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-κB signaling pathway.
Ma Y; Zhou G; Li M; Hu D; Zhang L; Liu P; Lin K
Neurochem Int; 2018 Sep; 118():233-241. PubMed ID: 29572052
[TBL] [Abstract][Full Text] [Related]
17. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
18. Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer.
Yip-Schneider MT; Wu H; Stantz K; Agaram N; Crooks PA; Schmidt CM
BMC Cancer; 2013 Apr; 13():194. PubMed ID: 23590467
[TBL] [Abstract][Full Text] [Related]
19. Cigarette Smoke Containing Acrolein Contributes to Cisplatin Resistance in Human Bladder Cancers through the Regulation of HER2 Pathway or FGFR3 Pathway.
Hong JH; Tong ZJ; Wei TE; Lu YC; Huang CY; Huang CY; Chiang CH; Jaw FS; Cheng HW; Wang HT
Mol Cancer Ther; 2022 Jun; 21(6):1010-1019. PubMed ID: 35312783
[TBL] [Abstract][Full Text] [Related]
20. JUND-dependent up-regulation of HMOX1 is associated with cisplatin resistance in muscle-invasive bladder cancer.
Peng Y; Chen Y; Chen S; Wang J; Jiang C; Hou W; Xu C
J Biochem; 2020 Jul; 168(1):73-82. PubMed ID: 32240302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
